Treatment
Ivonescimab clinical trials
We’re tracking 70 recruiting studies that include Ivonescimab, each written for real people, not researchers, below.
Recruiting studies
- NCT07359040Recruiting
Testing a new drug before surgery for lung cancer
This trial studies whether a new drug called Ivonescimab can improve outcomes when given before surgery for non-small cell lung cancer. It may help shrink tumors and make them easier to remove.
Beijing, Beijing MunicipalityAges Any age - NCT06875076RecruitingPhase 2
Ivonescimab plus chemotherapy for pretreated mesothelioma
This trial is testing a new immunotherapy drug (ivonescimab) combined with chemotherapy for people with mesothelioma that has already been treated. It aims to see if this combination can shrink tumors or slow the disease.
Changchun, JilinAges 1.5 years–6.3 years - NCT07245446RecruitingPhase 2
Ivonescimab for untreated extensive-stage SCLC
This study tests a new immunotherapy drug called ivonescimab for people with extensive-stage small cell lung cancer who have not had treatment before. The goal is to see if it can help shrink tumors and improve survival.
Beijing, Beijing MunicipalityAges 18–75 - NCT07244978RecruitingPhase 2
Immunotherapy plus chemotherapy before surgery for esophageal cancer
This trial tests whether giving a new immunotherapy drug (ivonescimab) along with standard chemotherapy before surgery can improve outcomes for people with resectable esophageal cancer. The goal is to shrink the tumor and increase the chance of successful surgery.
Hangzhou, ZhejiangAges 18–75 - NCT07226544RecruitingPhase 2
Ivonescimab before surgery for high-risk kidney cancer
This trial tests giving the drug ivonescimab before surgery for patients with high-risk clear cell kidney cancer. The goal is to see if it can help shrink the tumor and improve outcomes.
Duarte, CaliforniaAges 18 years+ - NCT07229417RecruitingPhase 2
Ivonescimab for metastatic lobular breast cancer
This trial tests a drug called ivonescimab for people with a specific type of breast cancer called invasive lobular carcinoma that has spread and is no longer responding to hormone therapy or is triple-negative. The goal is to see if it can shrink or slow the cancer.
Houston, TexasAges 18 years+ - NCT07228832RecruitingPhase 3
Study of two drugs with chemo for advanced colorectal cancer
This clinical trial tests a new drug, ivonescimab, against an approved drug, bevacizumab. Both are given with standard chemotherapy (FOLFOX) for people with advanced colorectal cancer that has not been treated yet with chemo or other drugs.
Mobile, AlabamaAges 18 years+ - NCT07208773RecruitingPhase 1/Phase 2
Study of YL201 and Ivonescimab for advanced solid tumors
This trial tests a new drug combination (YL201 and Ivonescimab) for people with advanced solid tumors that have stopped responding to other treatments. The goal is to see if this combination can shrink tumors or slow their growth.
Guangzhou, GuangdongAges 18 years+ - NCT07188103RecruitingPhase 2
Ivonescimab and short radiation for advanced esophageal cancer
This trial combines a targeted immunotherapy drug (ivonescimab) with a short course of radiation to treat advanced esophageal cancer that has worsened after first treatment. It aims to see if this combination can help when standard options have stopped working.
Hefei, AnhuiAges 18–80 - NCT07158489RecruitingPhase 2
New drug combo for advanced lung cancer after immunotherapy
This trial combines gemcitabine with ivonescimab to try to overcome resistance to immunotherapy in advanced non-small cell lung cancer. It's for people whose cancer has worsened after prior immunotherapy.
BadenAges 18 years+ - NCT07094685RecruitingPhase 2
Ivonescimab before surgery for head and neck cancer
This study tests a new immunotherapy drug called ivonescimab given before surgery for people with advanced head and neck cancer. The goal is to see if it helps shrink the tumor and improve outcomes.
Ann Arbor, MichiganAges 18 years+ - NCT07070466RecruitingPhase 2
Ivonescimab with chemotherapy for advanced stomach or esophageal cancer
This study tests a new drug called ivonescimab combined with standard chemotherapy (FOLFOX) for people with advanced adenocarcinoma of the esophagus, stomach, or gastroesophageal junction. The drug is designed to help the immune system fight cancer. The study is for people who have not had prior treatment for stage IV disease and whose cancer is HER2 negative.
Santa Monica, CaliforniaAges 18 years+ - NCT07017673RecruitingPhase 2
Ivonescimab with chemo for early-stage triple negative breast cancer
This trial tests a new drug, ivonescimab, combined with standard chemotherapy before surgery for people with high-risk early-stage triple negative breast cancer. The goal is to see if adding this drug improves treatment response.
Los Angeles, CaliforniaAges 18 years+ - NCT06980077RecruitingPhase 2
Ivonescimab for advanced thymic carcinoma
This trial tests a new drug called ivonescimab for thymic carcinoma that has come back or isn't responding to other treatments. It aims to see if this drug can shrink the cancer and help you feel better.
Davis, CaliforniaAges 18 years+ - NCT06959550RecruitingPhase 2
Ivonescimab for previously treated metastatic colorectal cancer
This trial tests a new drug called ivonescimab, which is a bispecific antibody that targets both PD-1 and VEGF. It is for people with metastatic colorectal cancer who have already tried standard treatments and may or may not have received immunotherapy before, depending on their tumor type.
Houston, TexasAges 18 years+ - NCT06951646RecruitingPhase 2
Personalized treatment for advanced lung cancer with long response to first-line therapy
This trial tests a combination of ivonescimab and docetaxel for people with advanced non-small cell lung cancer who have had a long response (11-15 months without the cancer getting worse) to first-line immunotherapy. The goal is to see if adjusting treatment based on ctDNA-MRD levels can improve outcomes.
ChangshaAges 18–75 - NCT06936488Enrolling by invitation
Study of Ivonescimab with TAS-102 for advanced colorectal cancer
This trial tests a combination of two drugs – ivonescimab (a type of immunotherapy) and TAS-102 (a chemotherapy) – for people with advanced colorectal cancer that has not responded to at least two prior chemotherapies. The goal is to see if this new combo can shrink tumors or slow cancer growth.
Huai'an, JiangsuAges 18–75 - NCT06925724RecruitingPhase 2
Ivonescimab for advanced endometrial or cervical cancer
This study tests a new drug called ivonescimab for people with advanced endometrial or cervical cancer that has progressed after standard platinum-based chemotherapy. Ivonescimab is an investigational immunotherapy that may help your immune system fight the cancer.
Basking Ridge, New JerseyAges 18 years+ - NCT06928389RecruitingPhase 3
Ivonescimab plus docetaxel for advanced lung cancer
This trial tests a new drug called ivonescimab combined with a chemotherapy drug (docetaxel) for advanced non-small cell lung cancer. It's for people who have already tried platinum-based chemo and a PD-1/PD-L1 inhibitor, and who have not had docetaxel before.
Shanghai, Shanghai MunicipalityAges 18–75 - NCT06848842RecruitingPhase 2
Ivonescimab and chemotherapy for colorectal cancer that spread only to the liver
This trial tests a new drug called ivonescimab combined with chemotherapy for people whose colorectal cancer has spread only to the liver and cannot be surgically removed right away. The goal is to see if this combination can shrink the tumors enough to allow surgery or other treatments.
BeijingAges 18 years+ - NCT06846346RecruitingPhase 2
Testing Ivonescimab with Chemo for Advanced Stomach Cancer
This trial tests a new immunotherapy drug called ivonescimab given together with standard chemotherapy for advanced stomach cancer. It may help your immune system fight the cancer more effectively.
LyonAges 18 years+ - NCT06844422RecruitingPhase 1/Phase 2
Guided radiation plus chemo and immune drug for pancreatic cancer
This study tests whether a new combination of super-precise radiation (guided SBRT), standard chemotherapy, and a newer immune medicine called Ivonescimab can slow or shrink pancreatic tumors that cannot be removed by surgery. The goal is to find a more effective treatment option.
Jinan, ShandongAges 18–75 - NCT06840834RecruitingPhase 2
New drug for mesothelioma that has returned after prior treatment
This trial tests a drug called ivonescimab for people with pleural mesothelioma (a cancer of the lung lining) that has grown back after earlier immunotherapy and chemotherapy. The drug may help by blocking a protein that tumors use to hide from the immune system, possibly slowing or shrinking the cancer.
BesançonAges 18 years+ - NCT06805617RecruitingPhase 2
Ivonescimab for advanced salivary gland cancer
This trial tests a new drug called Ivonescimab for people with advanced salivary gland cancer that has spread or cannot be removed surgically. The goal is to see if the drug can shrink tumors or slow cancer growth.
Boston, MassachusettsAges 18 years+
Common questions
- Are there clinical trials studying Ivonescimab?
- Yes. Clin2 currently lists 70 recruiting studies that include Ivonescimab, drawn from the U.S. registry and rewritten for real people so you can see what each is testing and who it's for.
- How do I know if I qualify for a Ivonescimab trial?
- Each study lists its own eligibility criteria — rules about condition, age, and prior treatments. On every Clin2 trial page we explain these in plain language and offer a short, optional pre-screen for a fit read. The study team makes the final decision.
- Is Ivonescimab an approved treatment?
- A drug being studied in a trial may be investigational (still being tested) or already approved and being studied for a new use. Each study page explains what phase it's in. Clin2 does not provide medical advice — talk with your doctor about whether Ivonescimab or a specific trial is right for you.
Related treatments
Clin2 helps you find and understand clinical trials and does not provide medical advice. Study data comes from ClinicalTrials.gov. A drug appearing here is being studied in a trial and may be investigational. Talk with your doctor about whether a specific treatment or trial is right for you.